Mark McKenna
Net Worth

Last updated:

What is Mark McKenna net worth?

The estimated net worth of Mr. Mark McKenna is at least $21,028,431 as of 6 Sep 2025. He has earned $14,988,431 from insider trading and has received compensation worth at least $6,040,000 in BlackRock, Inc. and Prometheus Biosciences, Inc..

What is the salary of Mark McKenna?

Mr. Mark McKenna salary is $1,510,000 per year as Pres, Chief Executive Officer & Chairman in Prometheus Biosciences, Inc..

What stocks does Mark McKenna currently own?

As insider, Mr. Mark McKenna owns shares in one company:

Company Title Shares Price per share Total value
Prometheus Biosciences, Inc. (RXDX) Pres, Chief Executive Officer & Chairman 55,144 $0 $0

What does Prometheus Biosciences, Inc. do?

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.

RXDX logo
RXDX
Prometheus Biosciences, Inc.

Mark McKenna insider trading

Prometheus Biosciences, Inc.

Mr. Mark McKenna has made 7 insider trades between 2021-2023, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 122,528 units of RXDX stock on 2 Jun 2023. As of 6 Sep 2025 he still owns at least 55,144 units of RXDX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 3 $1.7 $5
Option
Common Stock 3 $1.7 $5
Option
Common Stock 122,528 $2.9 $355,331
Option
Stock Option (Right to Buy) 122,528 $2.9 $355,331
Sale
Common Stock 25,000 $116.14 $2,903,500
Option
Common Stock 25,000 $2.9 $72,500
Option
Stock Option (Right to Buy) 25,000 $2.9 $72,500
Option
Common Stock 10,620 $3.7 $39,294
Sale
Common Stock 10,620 $125.13 $1,328,881
Option
Stock Option (Right to Buy) 10,620 $3.7 $39,294
Option
Stock Option (Right to Buy) 700 $3.7 $2,590
Option
Common Stock 700 $3.7 $2,590
Sale
Common Stock 700 $125.26 $87,682
Option
Common Stock 13,680 $3.7 $50,616
Sale
Common Stock 13,680 $125.1 $1,711,368
Option
Stock Option (Right to Buy) 13,680 $3.7 $50,616
Option
Stock Option (Right to Buy) 25,000 $3.7 $92,500
Sale
Common Stock 25,000 $119.87 $2,996,750
Option
Common Stock 25,000 $3.7 $92,500
Sale
Common Stock 25,000 $119.42 $2,985,500
Option
Stock Option (Right to Buy) 25,000 $2.9 $72,500
Option
Common Stock 25,000 $2.9 $72,500
Sale
Common Stock 25,000 $118.99 $2,974,750
Option
Stock Option (Right to Buy) 25,000 $2.9 $72,500
Option
Common Stock 25,000 $2.9 $72,500
Option
Common Stock 15,400 $2.9 $44,660
Option
Stock Option (Right to Buy) 15,400 $2.9 $44,660

BlackRock key executives

BlackRock, Inc. executives and other stock owners filed with the SEC:

  • Mr. Derek N. Stein Senior MD and Global Head of Technology & Operations
  • Mr. Gary Stephen Shedlin (62) Senior MD & Chief Financial Officer
  • Mr. J. Richard Kushel (58) Senior MD & Head of the Portfolio Management Group
  • Mr. Laurence Douglas Fink (73) Chairman & Chief Executive Officer
  • Mr. Marc David Comerchero CPA, CPA MD & Chief Accounting Officer
  • Mr. Mark McKenna Founder, MD, Global Head of Event Driven Equity Strategies & Portfolio Mang.
  • Mr. Robert Lawrence Goldstein (51) Senior MD, Chief Operating Officer & Global Head of BlackRock Solutions
  • Mr. Robert Steven Kapito (69) Pres & Director
  • Ms. Barbara Goldman Novick Co-founder & Vice Chairman
  • Ms. Sandra L. Boss Senior MD & Global Head of Investment Stewardship